RU2661879C2 - ИНГИБИТОРЫ ЦИСТАТИОНИН-γ-ЛИАЗЫ (CSE) - Google Patents

ИНГИБИТОРЫ ЦИСТАТИОНИН-γ-ЛИАЗЫ (CSE) Download PDF

Info

Publication number
RU2661879C2
RU2661879C2 RU2015105700A RU2015105700A RU2661879C2 RU 2661879 C2 RU2661879 C2 RU 2661879C2 RU 2015105700 A RU2015105700 A RU 2015105700A RU 2015105700 A RU2015105700 A RU 2015105700A RU 2661879 C2 RU2661879 C2 RU 2661879C2
Authority
RU
Russia
Prior art keywords
pain
compound
formula
unsubstituted
alkyl
Prior art date
Application number
RU2015105700A
Other languages
English (en)
Russian (ru)
Other versions
RU2015105700A (ru
Inventor
Серджио Г. Дюрон
Джастин ЧАПМЭН
Саймон Г. СИДСЕРЕФФ
Сринивас Г. Рао
Грегори ШТЕЙН
Уоррен Уэйд
Original Assignee
Сова Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сова Фармасьютикалс, Инк. filed Critical Сова Фармасьютикалс, Инк.
Publication of RU2015105700A publication Critical patent/RU2015105700A/ru
Application granted granted Critical
Publication of RU2661879C2 publication Critical patent/RU2661879C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/61—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2015105700A 2012-07-25 2013-07-23 ИНГИБИТОРЫ ЦИСТАТИОНИН-γ-ЛИАЗЫ (CSE) RU2661879C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675754P 2012-07-25 2012-07-25
US61/675,754 2012-07-25
PCT/US2013/051745 WO2014018570A1 (en) 2012-07-25 2013-07-23 Cystathionine-υ-lyase (cse) inhibitors

Publications (2)

Publication Number Publication Date
RU2015105700A RU2015105700A (ru) 2016-09-10
RU2661879C2 true RU2661879C2 (ru) 2018-07-20

Family

ID=49997791

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015105700A RU2661879C2 (ru) 2012-07-25 2013-07-23 ИНГИБИТОРЫ ЦИСТАТИОНИН-γ-ЛИАЗЫ (CSE)

Country Status (13)

Country Link
US (2) US9725426B2 (enExample)
EP (1) EP2877457B1 (enExample)
JP (1) JP6391071B2 (enExample)
KR (1) KR20150041635A (enExample)
CN (1) CN104662007B (enExample)
AR (1) AR091857A1 (enExample)
AU (2) AU2013293090A1 (enExample)
CA (1) CA2879879C (enExample)
HK (1) HK1210614A1 (enExample)
IN (1) IN2015DN01161A (enExample)
RU (1) RU2661879C2 (enExample)
TW (1) TWI684583B (enExample)
WO (1) WO2014018570A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2841071C1 (ru) * 2023-12-14 2025-06-02 Автономная некоммерческая образовательная организация высшего образования "Научно-технологический университет "Сириус" Способ ингибирования бактериальной цистатионин-γ-лиазы

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
AR091857A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9643942B2 (en) * 2014-02-28 2017-05-09 Zeon Corporation Method for manufacturing 1,1-disubstituted hydrazine compound
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
BR112017000468A2 (pt) * 2014-07-09 2017-11-07 Sun Pharmaceutical Ind Ltd forma de dosagem de cápsula de liberação prolongada
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
WO2016160885A1 (en) 2015-03-30 2016-10-06 Farmington Pharma Development Creatine phosphate analog prodrugs, compositions and uses thereof
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11332438B2 (en) 2017-12-01 2022-05-17 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof
US12667087B2 (en) 2019-06-07 2026-06-30 Agios Pharmaceuticals, Inc. Methods of treatment with aminolevulinic acid synthase 2 (ALAS2) modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005369B1 (ru) * 1999-03-15 2005-02-24 Аксис Фармасьютикалз, Инк. Новые соединения и композиции в качестве ингибиторов протеазы

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD13769A (enExample) *
DE13769C (de) W. H. MC. NARY in Brooklyn (Staat New-York, V. St. A.); Vertreter : F. E. THODE & KNOOP in Dresden, Augustusstrafse 3 II Neuerungen an flachen Kettenstühlen
DE207626C (enExample) * 1900-01-01
NL6402073A (enExample) 1963-03-05 1964-09-07
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
DD207626A3 (de) * 1981-12-17 1984-03-07 Manfred Just Verfahren zur herstellung des 3-amino-5-hydrazino-1,2,4-triazols und dessen derivaten
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4610717A (en) * 1985-11-26 1986-09-09 Shell Oil Company Certain 5-(R-oxy)-1-phenyl or (3-(trifluoromethyl)phenyl)triazoles, useful for controlling undesired plant growth
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
WO2005103012A1 (ja) 2004-04-21 2005-11-03 Ono Pharmaceutical Co., Ltd. ヒドラジノ複素環ニトリル化合物およびその用途
AR091857A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005369B1 (ru) * 1999-03-15 2005-02-24 Аксис Фармасьютикалз, Инк. Новые соединения и композиции в качестве ингибиторов протеазы

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Linda J.EJIM et al. Inhibitors of Bacterial Cystathionine beta-Lyase: Leads for New Antimicrobial Agents and Probes of Enzyme Structure and Function, Journal of Medicinal Chemistry, 2007, Vol: 50, Page(s): 755-764. *
PubChem compound, Hydrazinesulfonic acid (CID:0313107; create date 25.10.2006), PubChem datasheet retrieved from the internet. PubChem compound, Hydrazinesulfonic acid (CID:0313107; create date 25.10.2006), PubChem datasheet retrieved from the internet. *
PubChem compound, Hydrazinesulfonic acid (CID:0313107; create date 25.10.2006), PubChem datasheet retrieved from the internet. PubChem compound, Hydrazinesulfonic acid (CID:0313107; create date 25.10.2006), PubChem datasheet retrieved from the internet. SATZINGER G.5-Substituierte und 1.5-kondensierte Tetrazole, JUSTUS LIEBIGS ANNALEN DER CHEMIE, 1960, Vol: 638, Page(s): 159-173. QINGZIANG SUN et al. Structural Basis for the Inhibition Mechanism of Human Cystathionine -Lyase, an Enzyme Responsible for the Production of H2S, Journal of Biological Chemistry, 2009, Vol: 284, Nr: 5, Page(s): 3076-3085. Linda J.EJIM et al. Inhibitors of Bacterial Cystathionine beta-Lyase: Leads for New Antimicrobial Agents and Probes of Enzyme Structure and Function, Journal of Medicinal Chemistry, 2007, Vol: 50, Page(s): 755-764. *
QINGZIANG SUN et al. Structural Basis for the Inhibition Mechanism of Human Cystathionine -Lyase, an Enzyme Responsible for the Production of H2S, Journal of Biological Chemistry, 2009, Vol: 284, Nr: 5, Page(s): 3076-3085. *
SATZINGER G.5-Substituierte und 1.5-kondensierte Tetrazole, JUSTUS LIEBIGS ANNALEN DER CHEMIE, 1960, Vol: 638, Page(s): 159-173. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2841816C1 (ru) * 2023-11-29 2025-06-17 Автономная некоммерческая образовательная организация высшего образования "Научно-технологический университет "Сириус" МОЛЕКУЛЫ-ИНГИБИТОРЫ БЕЛКА БАКТЕРИАЛЬНОЙ ЦИСТАТИОНИН-γ-ЛИАЗЫ
RU2841071C1 (ru) * 2023-12-14 2025-06-02 Автономная некоммерческая образовательная организация высшего образования "Научно-технологический университет "Сириус" Способ ингибирования бактериальной цистатионин-γ-лиазы

Also Published As

Publication number Publication date
JP6391071B2 (ja) 2018-09-19
AU2013293090A1 (en) 2015-02-19
EP2877457A1 (en) 2015-06-03
CA2879879A1 (en) 2014-01-30
AR091857A1 (es) 2015-03-04
AU2018200632A1 (en) 2018-02-15
CN104662007A (zh) 2015-05-27
TW201406711A (zh) 2014-02-16
KR20150041635A (ko) 2015-04-16
US20150266837A1 (en) 2015-09-24
JP2015524807A (ja) 2015-08-27
CA2879879C (en) 2020-09-08
CN104662007B (zh) 2018-03-16
AU2018200632B2 (en) 2019-10-24
IN2015DN01161A (enExample) 2015-06-26
EP2877457A4 (en) 2016-04-20
US9725426B2 (en) 2017-08-08
EP2877457B1 (en) 2020-09-23
US20170327478A1 (en) 2017-11-16
HK1210614A1 (en) 2016-04-29
RU2015105700A (ru) 2016-09-10
WO2014018570A1 (en) 2014-01-30
TWI684583B (zh) 2020-02-11

Similar Documents

Publication Publication Date Title
JP6391071B2 (ja) シスタチオニン−γ−リアーゼ（ＣＳＥ）阻害剤
RU2640418C2 (ru) Ингибиторы цистатионин-г-лиазы (cse)
US20150272934A1 (en) Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders
US20150202186A1 (en) CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
US11161849B2 (en) Inhibiting the transient receptor potential al ion channel
US20210198238A1 (en) Ire1 kinase inhibitors and uses thereof
JP2009522287A (ja) 脂肪酸アミド加水分解酵素阻害剤
JP2010505844A (ja) Ｓ−ニトロソチオール化合物および関連誘導体
CN104447682A (zh) 比拉斯汀化合物
CN101351495A (zh) 脂肪酸酰胺水解酶抑制剂
WO2006082771A1 (ja) １‐アミノシクロプロパンカルボン酸等を主成分とする脳卒中又は脳卒中後遺症の予防用又は治療用薬剤